Compliance Radar
Who was sanctioned, and for what?
Fines, court rulings and incidents from Europe, North America, Latin America and Asia-Pacific: 1,869 cases from 39 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.
Click a bar to drill down one level.
Where?
by regionAll jurisdictions
What for?
by area of lawAll areas of law
Who?
by company- Anonymised companies 4 cases 11 % · €49.1m
- ExxonMobil Chemical Limited 2 cases 5 % · €513,011
- AFCO (Tochtergesellschaft der Zep Inc.) 1 case 3 % · €157,452
- Alchem International Pvt. Ltd. und Alchem International (H.K.) Limited 1 case 3 % · €489,000
- Ballance Agri-Nutrients Limited 1 case 3 % · €223,678
- Boehringer Ingelheim, Alkaloids of Australia, C2 PHARMA u. a. (7 Unternehmen) 1 case 3 % · €645,231
- Colorcon Limited 1 case 3 % · €176,590
- Denka Performance Elastomer, LLC 1 case 3 % · €874,915
- Dompé U.S. Inc. 1 case 3 % · €27.5m
- Estee Lauder Cosmetics Ltd. 1 case 3 % · €463,765
- 24 more24 cases
When?
per quarter, by date of decision| Period | Cases | Total |
|---|---|---|
| Q4 2023 | 0 | – |
| Q1 2024 | 0 | – |
| Q2 2024 | 0 | – |
| Q3 2024 | 0 | – |
| Q4 2024 | 1 | €411.6m |
| Q1 2025 | 0 | – |
| Q2 2025 | 0 | – |
| Q3 2025 | 0 | – |
| Q4 2025 | 0 | – |
| Q1 2026 | 0 | – |
| Q2 2026 | 0 | – |
| Q3 2026 | 0 | – |
| Q4 2026 | 0 | – |
1 case
10 Oct 2024 Teva Pharmaceuticals USA, Inc. und Teva Neuroscience, Inc.Teva: USD 450m settlement over copay support and price fixing as kickbacks €411.6m
Teva pays USD 450 million to resolve two sets of allegations under the Anti-Kickback Statute and the False Claims Act; the amount was based on its ability to pay. First, from 2006 to 2017 Teva allegedly funded Medicare copays for the MS drug Copaxone through two purportedly independent foundations and a specialty pharmacy while steadily raising the price; second, benefits from price fixing with other generic manufacturers (pravastatin, clotrimazole, tobramycin), for which Teva USA had already entered into a criminal DPA with USD 225 million, were treated as unlawful kickbacks.
Donations to patient assistance foundations must never be linked to the copays for one's own drugs.
Donations to patient assistance foundations and copay programmes
- Authority / court
- U.S. Department of Justice (Civil Division; USAO District of Massachusetts; USAO Eastern District of Pennsylvania)
- Area of law
- Bribery and corruption · Gifts, hospitality and benefits
- Legal basis
- False Claims Act; Anti-Kickback Statute
- Action
- Other
- Status of proceedings
- final
- Sector
- Chemicals and pharmaceuticals
- Mitigating circumstances
- The settlement amount was based on Teva's ability to pay.
- Published
- 10 Oct 2024
Original amount 450,000,000 USD, converted at the ECB reference rate of 10 Oct 2024.
- Drug Maker Teva Pharmaceuticals Agrees to Pay $450M in False Claims Act Settlement to Resolve Kickback Allegations Relating to Copayments and Price Fixing (DOJ, 10.10.2024) Press release of an authority
- Teva Pharmaceuticals Agrees to Pay $425 Million to Resolve Kickback Allegations (USAO D. Mass., 10.10.2024) Press release of an authority
Checked against the official source on 3 Oct 2026 · Direct link